Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease

Details for Australian Patent Application No. 2004260700 (hide)

Owner Epigenesis Pharmaceuticals LLC

Inventors Robinson, Cynthia B.; Ball, Howard A.

Agent Fisher Adams Kelly

Pub. Number AU-B-2004260700

PCT Pub. Number WO2005/011603

Priority 60/492,232 31.07.03 US; 10/698,078 26.10.03 US

Filing date 30 July 2004

Wipo publication date 10 February 2005

Acceptance publication date 20 January 2011

International Classifications

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

23 February 2006 PCT application entered the National Phase

  PCT publication WO2005/011603 Priority application(s): WO2005/011603

23 March 2006 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 15 Feb 2006

20 January 2011 Application Accepted

  Published as AU-B-2004260700

19 May 2011 Standard Patent Sealed

23 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004260702-Combination therapies for Multiple Sclerosis

2004260699-Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease